Skip to content
Pass Duke Elder
Textbook / Chapter 11 / Strabismus and paediatric ophthalmology

Retinopathy of prematurity

Retinopathy of prematurity is a disease of retinal blood vessels that have not finished growing when a baby is born too early. It is one of the few largely preventable causes of childhood blindness, because a screening programme finds it and treatment works. This lesson explains why it happens, who is screened in the UK and when, how it is classified by zone, stage and plus disease, and how it is treated.

10 minute read6 linked questions

Retinal vessels grow late

The retina is one of the last tissues in the body to get its blood supply. Vessels begin to grow out from the optic disc at about 14 to 16 weeks of gestation and spread towards the edge of the retina, the ora serrata, like ripples from a stone. They are drawn forwards by vascular endothelial growth factor (VEGF), which is released by retina that has not yet been reached and is short of oxygen. The disc lies nearer the nasal edge than the temporal edge, so the nasal retina is covered first and the far temporal retina last, late in the third trimester.

A baby born very early therefore has a retina with vessels at the back and bare, avascular retina at the front. The more premature the baby, the larger the bare area and the closer its border lies to the disc and macula. Retinopathy of prematurity (ROP) is what happens when vessel growth across that bare retina first stalls and then restarts in a disordered way.

3D atlasRetinal vessels grow from the optic disc towards the ora serrata. In a preterm baby the peripheral retina, especially on the temporal side, has no vessels yet.

Two phases: too little VEGF, then too much

The disease is easiest to remember as two phases, which also explain the timing of screening and the logic of treatment.

Phase 1, vessel growth stops. In the womb the fetus lives at a low oxygen level, and that relative hypoxia is what keeps VEGF flowing. After a preterm birth the baby breathes air or supplemental oxygen, the retina is suddenly well oxygenated, and VEGF production falls. Circulating levels of insulin-like growth factor 1 (IGF-1), which vessels need in order to respond to VEGF, are also low after preterm birth. Vessel growth slows or stops, and some new capillaries are lost. The Royal College of Ophthalmologists guideline places this phase before about 30 weeks of postmenstrual age (gestational age at birth plus weeks since birth).

Phase 2, vessels grow wildly. As the weeks pass the bare peripheral retina matures and its demand for oxygen rises, but it still has no vessels. It becomes hypoxic and pours out VEGF. From about 31 weeks of postmenstrual age, high VEGF together with recovering IGF-1 levels drives new vessels to sprout at the border between vascular and avascular retina. Instead of growing forwards within the retina, they grow up into the vitreous. These fragile vessels bring fibrous tissue with them, which can contract and pull the retina off.

This explains the risk factors. The dominant ones are low gestational age and low birthweight. Supplemental oxygen, poor postnatal weight gain and the other complications of prematurity add to the risk. Oxygen is a balance: neonatal units control oxygen saturation tightly, because high and fluctuating levels promote ROP while targets set too low have been linked to higher mortality.

Who is screened in the UK, and when

ROP gives no outward sign until it is advanced, and the window for treatment is short, so babies at risk are examined on a schedule. The UK guideline is published by the Royal College of Paediatrics and Child Health with the Royal College of Ophthalmologists and the British Association of Perinatal Medicine (2022, revised 2024).

  • Who: all babies born at less than 31 weeks of gestation (up to and including 30 weeks and 6 days) or with a birthweight of less than 1501 g. Meeting either criterion is enough.
  • The 2024 revision added that babies born between 31 weeks 0 days and 31 weeks 6 days should be considered for screening.
  • First examination, babies born before 31 weeks: at 31 weeks 0 days to 31 weeks 6 days of postmenstrual age, or at 4 completed weeks after birth, whichever is later.
  • First examination, babies born at 31 weeks or later: at 36 weeks 0 days to 36 weeks 6 days of postmenstrual age, or at 4 completed weeks after birth, whichever is sooner.
  • After that: at least weekly if the vessels end in zone I or posterior zone II, if there is any plus or pre-plus disease, or if there is stage 3 disease. Otherwise at least every two weeks.
  • Stopping: in a baby with no ROP, when vessels have reached zone III, which is unlikely before 36 weeks of postmenstrual age. In a baby with ROP, when it is clearly regressing on at least two consecutive examinations.

The timing follows from the two phases. Phase 2 does not begin until about 31 weeks of postmenstrual age however early the baby was born, so examining sooner finds nothing and stresses a fragile baby.

The examination is done on the neonatal unit by an ophthalmologist using binocular indirect ophthalmoscopy, or with a wide-field digital retinal camera. The pupils are dilated beforehand with phenylephrine 2.5% and cyclopentolate 0.5%, and topical anaesthetic is given if a lid speculum is used.

Describing ROP: zone, stage and plus

ROP is recorded using the International Classification of Retinopathy of Prematurity. Each eye gets a location (zone), a severity (stage), an extent in clock hours and a statement about plus disease.

Zones say how far the vessels have reached. They are centred on the optic disc, not the macula, because that is where the vessels start. The lower the zone number, the more immature the retina and the more dangerous the disease.

  • Zone I: a circle around the disc whose radius is twice the distance from the disc to the centre of the macula.
  • Zone II: a ring from the edge of zone I out to the nasal ora serrata.
  • Zone III: the remaining crescent of temporal retina.
StageWhat is seen at the border of vascular and avascular retina
1A thin flat white demarcation line
2A ridge: the line has gained height and width
3A ridge with new vessels and fibrous tissue growing off it into the vitreous (extraretinal fibrovascular proliferation)
4Partial retinal detachment: 4A spares the fovea, 4B involves it
5Total retinal detachment
The five stages of ROP

Plus disease is dilatation of the veins and tortuosity of the arterioles at the posterior pole. It shows that the eye is being driven hard by VEGF and is a key sign that treatment may be needed. Pre-plus is vessel change that is abnormal but not enough for plus. For treatment decisions in the UK, plus disease must be present in at least two quadrants.

Aggressive ROP (A-ROP) is a rapidly progressing form, usually in the most immature babies and in posterior retina. It can go from early changes to detachment within days without passing through the stages in order, and it shows marked plus disease with flat, easily missed new vessels.

Most ROP is mild. Stages 1 and 2 usually regress by themselves as the vessels resume normal growth. In a UK national study in 2014, only about 4% of screened babies needed treatment, and those babies had a median gestational age of 25 weeks and a median birthweight of 706 g.

When and how to treat

The treatment thresholds come from the American ETROP trial, which showed that treating high-risk disease early gave better vision and retinal structure than waiting for the older, more advanced threshold. The Royal College of Ophthalmologists guideline (2022) says to treat when screening finds any of the following.

  • Zone I, any stage, with plus disease.
  • Zone I, stage 3, without plus disease.
  • Zone II, stage 2 or 3, with plus disease. Zone II stage 2 with plus is regarded as borderline, and close observation is an accepted alternative.
  • Aggressive ROP.

Treatment is urgent. Babies with aggressive ROP, or zone I stage 3 with plus disease, should be treated as soon as possible and within 48 hours. The others should be treated within 48 to 72 hours.

Both treatments work by lowering VEGF inside the eye. Laser photocoagulation is applied through an indirect ophthalmoscope to the whole of the avascular peripheral retina. It destroys the hypoxic tissue that is making the VEGF, and the abnormal vessels then regress. Anti-VEGF injection into the vitreous (ranibizumab or bevacizumab) binds the VEGF directly. Cryotherapy, the original treatment, has been replaced by laser.

LaserAnti-VEGF injection
MechanismAblates the avascular retina that produces VEGFNeutralises VEGF in the vitreous
Peripheral retinaPermanently destroyedPreserved, and vessels may continue to grow outwards
DurabilityMore definitiveDisease can reactivate weeks later, so follow-up is longer and more intensive and retreatment is more often needed
High myopia laterMore commonLess common
Systemic concernsNone from the treatment itself, but takes longer and is more demanding for an unstable babyDrug reaches the circulation, and long-term developmental safety is still being studied
UK guideline positionRemains the preferred treatment for most babiesRecommended for aggressive ROP and for zone I and posterior zone II disease. In zone II, preferred for babies too unstable for laser and when the view of the fundus is poor. Ranibizumab is the only anti-VEGF drug licensed for ROP
Laser and anti-VEGF for ROP compared

Once the retina has started to detach (stages 4 and 5), laser and injections are no longer enough and vitreoretinal surgery is considered at a specialist centre. Results at that point are poor, which is the reason the screening programme exists.

After ROP

Regressed or treated ROP is not the end of eye care. Children who were born very preterm, and especially those who had ROP, have higher rates of myopia, strabismus, anisometropia and amblyopia, and the UK screening guideline asks that parents are told about the risk of refractive error and squint when screening ends. Babies who needed treatment are followed in the eye clinic through childhood with refraction and orthoptic assessment. Scarring that drags the macula towards the temporal side can make the eyes look divergent when they are not, a form of pseudosquint. Late retinal detachment can occur in eyes with scarring.

The end stage of untreated ROP is a white fibrovascular mass behind the lens, the appearance that gave the disease its old name of retrolental fibroplasia. It is one of the causes of a white pupil in infancy, discussed in the next lesson.

Summary

  • Retinal vessels grow outwards from the disc from about 14 to 16 weeks of gestation and reach the temporal periphery last, late in the third trimester.
  • In phase 1 of ROP, relative hyperoxia and low IGF-1 after preterm birth halt vessel growth, and in phase 2 the hypoxic avascular retina releases VEGF that drives abnormal new vessels.
  • The main risk factors are low gestational age and low birthweight.
  • UK screening covers babies born at less than 31 weeks of gestation or weighing less than 1501 g.
  • The first examination is at 31 weeks of postmenstrual age or 4 weeks after birth, whichever is later, for babies born before 31 weeks.
  • Zone I surrounds the disc with a radius of twice the disc to macula distance, and disease in zone I is the most dangerous.
  • Stage 1 is a line, stage 2 a ridge, stage 3 extraretinal proliferation, stage 4 partial detachment and stage 5 total detachment.
  • Plus disease is venous dilatation and arteriolar tortuosity at the posterior pole and signals the need for treatment.
  • Treatment is indicated for zone I disease with plus or at stage 3, zone II stage 2 or 3 with plus, and aggressive ROP, within 48 to 72 hours.
  • Laser to the avascular retina is the usual UK treatment, with anti-VEGF injection recommended for zone I disease and aggressive ROP and preferred for unstable babies.

Check yourself

Quick recall on this lesson. These are easier than the question bank.

1. Under the current UK guideline, which baby meets the criteria for ROP screening?
2. Plus disease in ROP refers to:
3. Stage 3 ROP is defined by:
4. Laser treatment for ROP is applied to:
Practise 6 questions on this lesson

Written for revision. It is not a source of clinical advice, and guidance changes.